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Abstract. The strategic action plan on antibiotic resistance with the slogan “No action today, no cure tomorrow” was 
marketed at the World Health Organization Day in 2011. From this event the key strategic actions started to mitigate, 
prevent and control antibiotic consumption and resistance. These include: promoting the prudent multifaceted use of 
antibiotics; strengthening surveillance systems, monitoring the use of antibiotics to bacteria resistance and others. In the 
EMI a considerable decrease of antibiotics consumption was registered in the evaluated period from 662.4 to 464.1 
DDD/1000.
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values, natural
Rezumat
Supravegherea consumului de antibiotice în spitale
La aniversarea Zilei Organizaţiei Mondiale a Sănătăţii pe data de 7 aprilie 2011, petrecută sub sloganul “Nu vom acţiona 
astăzi, nu vom trata mâne” a fost aprobat Planul strategic de retenţie antimicrobiană. Ca cheie a planului s-a lansat atenuarea 
şi controlul asupra consumului asigurarea utilizării raţionale de antibiotice, precum şi controlul asupra rezistenţei 
antimicrobiene şi altele. în IMU în perioada evaluată s-a înregistrat o descreştere a consumului de antibiotice de la 662.4 
până la 464.1 DDD/1000.
Cuvinte cheie: medicamente, asigurare, antibiotice, doza definită pentru o zi, consum, utilizare raţională, spitale, zi pat 
ocupat, indice, valoare, natural________________________
Introduction
In developing and transitional countries, in primary care 
less than 40% of patients in the public sector are treated in 
accordance with standard treatment guidelines, [1]. There 
are numerous sources of data that include drugs dispensed in 
hospitals, [2-5]. Nevertheless in the Republic of Moldova 
analysis in DDD, as an important indicator of optimal 
rational use of drug remedies generally, and of anti-infective 
for systemic use ones, in particular, is not studied enough 
and highlighted by scientific research literature.
National Scientific-Practical Centre of Emergency 
Medicine of the Republic of Moldova reorganised in 2014 
in Emergency Medical Institute (EMI), was founded in 
1957. The whole Institution include 650 beds overall. There 
are 4 outpatient departments of traumatology and 
orthopaedics as well, [6].
The primary aim of the study was to evaluate 
institutional representative data on antibiotics utilization for 
six years (2009-2014) period, in accordance to World 
Health Organization (WHO) requirements, projected to 
determine value of Defined Daily Doses per 1000 Occupied- 
Bed Days (DDD/1000), [7]. That study was carried out in 
accordance with World Health Organization (WHO) DDD 
program and with the support of other two programs that 
were effectuated in the institution “Analysis program of
consumption and stocks of drugs Anatomical Therapeutical 
Chemical” and “Pharmacotherapeutic software”. Based on 
the obtained data, it aimed to make conclusions on the use 
of anti-infective for systemic use in the medical institutions 
and to propose recommendations for ensuring their 
optimization.
Material and methods
For this study we used data on a six-year (2009-2014) 
period, in the Public Health Institution, Emergency 
Medicine Institute (EMI), which show the dynamics of 
consumption of medicinal remedies pharmaco - therapeutic 
group J -  Anti-infective for systemic use, as classified 
Anatomical Therapeutic Chemical classification system of 
World Health Organization (ATC) indicating the nature and 
value indexes. Statistical, analytical, mathematical, 
comparisons, logical and descriptive were used as the 
methods of study.
The results of the investigation and their analysis
To determine DDD and to compare the consumption of 
anti-infective for systemic use drugs for the period of 2009­
2014, the statistics data concerning the number of treated 
patients (for only patients with health insurance and other 
free treated by the state categories of citizens), the number 
of bed/days and total annual quantities of medicines were
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Figure 1. The antibiotics share from all annual drugs consumption in 2014 in lei.
From figure 1 we find that the total consumption of drugs 
in 2014 constituted 11 084 624 (lei), from which in 
accordance with ATC classification anti-infective for 
systemic use consisted 1 500 888 lei or 14%, that are with 
some deviation (2-3%) the same for more years, [8, 9].
The DDD for any drug is defined as the average 
dose per day for treatment the main indication for an 
average adult patient.
The World Health Organization (WHO) has determined 
DDDs standards for most drugs and these values have been 
used in calculating usage rates. To determine value of 
Defined Daily Doses per 1000 Occupied-Bed Days 
(DDD/1000) we followed 10 steps of study recommended 
by WHO for every antimicrobial evaluated remedies, [10]. 
The DDD of antibiotics publicised by World Health 
Organization and utilizing in EMI in table 1 is shown.
Table I
The DDD of antibiotics determined by World Health Organization and utilizing in EMI





J ANTIINFECTIVES FOR SYSTEMIC USE







J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS





JO ICR Combinations ofpenicillinc, inch beta-lactamase inhibitors
Amoxicillinum + Acidum clavulanicum o 1
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Amoxicillinum + Acidum clavulanicum P 3
Ticarcillinum + Acidum clavulanicum P 15
J01D  O T H E R  B E T A -L A C T A M  A N T IB A C T E R IA L S













Cefoperazonum + Sulbactamum P 4
J01D H  C arbapenem s
Meropenemum P 2
Imipenemum+Cilastatinum P 2
J01E  S U L F O N A M ID E S  A N D  T R IM E T H O P R IM
J01E E  C om b in ation s o f  su lfon am id es and  tr im eth op rim , in c l. derivatives
Sulfamethoxazolum + Trimethoprimum O 1,9
J 01F  M A C R O L ID E S , L IN C O S A M ID E S  A N D  S T R E P T O G R A M IN S




















Acidum pipemidicum 0 0,8
Acidum pipemidicum P 0,8
J01R COMBINATIONS OF ANTIBACTERIALS
Ciprofloxacinum + Tinidazolum 0 2
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All in all 50 antimicrobial remedies (both for parenteral 
and enteral use) treating assistance of hospitalized patients 
in the evaluated period were used, from which with only 
enteral form 12 names, with only parenteral form 18 names
and with both forms 10 names, which represents 40 active 
antimicrobial substances, [11]. Cephalosporins consumption 
rate of enteral forms in DDD/1000 during 2009-2014 is 
presented in figure 2.
Figure 2. Cephalosporins consumption rate of enteral forms in DDD/1000 during 2009-2014.
From this figure as one can see the intake of enteral 
forms cephalosporins G-I (first generation) reveals an 
increment by 10.7 times, G-II the second generation by 22.2 
times, G-III the third generation) by 4.3 times and increase 
for whole groups has changed from 2.2 in 2009 to 25.3 
DDD/1000 in 2014 or by 11.5 times. Cephalosporins 
consumption rate of parenteral forms in DDD/1000 during 
2009-2014 in figure 3 is presented.
In figure nr. 3 consumption of parenteral forms of 
cephalosporins is shown. A decrease by 2.45 times was 
registered for cephalosporin's G-I, and an increment for G-II 
and G-III by 2 and 2.79 times respectively. All in all, the 
consumption of three generation groups of cephalosporin's 
faces to a slight decrease from 268.5 to 247.3 DDD/1000 or 
with 7.9%. In figure 4 the cephalosporins consumption rate 
of parenteral and enteral forms in DDD/1000 during 2009­
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Figure 3. Cephalosporins consumption rate of parenteral forms in DDD/1000 during 2009-2014.
Figure 4. Cephalosporins consumption rate of parenteral and enteral forms in DDD/1000 during 2009-2014.
From this chart as one can see the total consumption of 
parenteral and enteral forms of ce-phalosporin’s G-I (in the 
evaluated period) has decreased with 49.63%, and 
cephalosporin’s G-II and G-III has increased from 78 (16.1 
+ 61.9) in 2009 to 173.9 DDD/1000 (49.4 + 124.5) 
respectively or by 2.3 times. The total consumption of the 
group encounters a slight increase from 270.7 to 272.6 
DDD/1000 or with 0.7%, with some deviations in 2010 and 
2012.
In figure 5 it is shown the total consumption rate 
subgroups of antibiotics (enteral and parenteral forms) in 
DDD/1000 during 2009-2014.
In this figure the total (parenteral and enteral forms) 
antibiotic groups used rates is demonstrated. The average 
aggregated annual rate for total-hospital antibiotics 
utilization period decreased from 662.4 in 2009 to 464.1 
DDD/1000 OBD in 2014 or by 30%.
The rate of parenteral form (P) to enteral (O) from and 
total (T) consumption of antibiotics in DDD/1000 during 
2009-2014 is shown in figure 6.
From this figure as one can see a decline with 11.1 % 
(85.9% - 74.8%) for parenteral and an encrease oral usage 
with 11.1 % (14.1% - 25.2%) had been recorded. That fact 
could be observed from this chart.
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Figure 5. Total consumption rate subgroups of antibiotics (enteral and parenteral forms) in DDD/1000 during
2009-2014.
2009 2010 2011 2012 2013 2014
□ Total parenteral ■ Total oral ■TOTAL
Figure 6. The rate of parenteral form (P) to enteral (O) from total (T) consumption of antibiotics in DDD/1000
during 2009-2014.
In figure 7 the average maximum and minimum consumption of antibiotics of DDD/1000 in European Union countries 
hospitals and EMI is shown.
Figure 7. The average maximum and minimum consumption of antibiotics of DDD/1000.
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In this chart the average maximum and the minimum 
consumption of antibiotics in DDD/1000 is shown in the 
period 2009-2014 between Public Health Care Institution 
EMI and more than 1500 European Union hospitals in 
comparison. As one may see the total consumption of 
antibiotics was recorded 662.4 DDD/1000 in 2009, which 
was more than average maximum consumption, registered
in some hospitals of EU countries, consisting 162.4 
DDD/1000. In 2014 the consumption was reduced to 464.1 
or in other words the decrease was up to 198.3 DDD/1000 
or by 30% in comparison with 2009. In figure 8 it is shown 
the seasonal pattern - the antibiotic use depending on the 
strength of Escherichia Coli.
Figure 8. The seasonal pattern - the antibiotic use depending on the strength of Escherichia Coli.
The study of pathogenic microbes’ resistance in 
dependence on the seasonal temperature throughout the year 
is an important direction in the achieving high progress in 
antimicrobial treatment. As one may see at this chart, the 
thorough analysis performed by American scientists in more 
than 300 hospitals in the US in the period of 1999-2007, the 
consumption of aminopenicillins for treatment infected 
patients caused by E.coli is much higher during cold period 
(November, December, January, February, March and a part 
of April), than hot period of the year (May, June, July, 
August, September and November) [12].
Because of different opinions on the preoperative 
antimicrobial prophylaxis under the leadership of professor 
Gheorghe Ciobanu, chief of Urgent Medicine Department of 
SMFU by “N. Testimitanu” was elaborated the institutional 
guide of “Antibiotic prevention of surgical infection” [13].
The content of the guide confirmed that the 
cephalosporin’s I and II generations are used in 85 -  90% 
cases for preoperative antimicrobial prophylaxis in surgery 
and traumatology investigations.
Conclusions:
1. In EMI a considerable decrease of antibiotics consumption was registered in the period 2009 -2014. The DDD/1000 in 
2009 constituting 662.4 unites was with 162.4 unites more than the medium maximum in more hospitals of EU countries. 
In 2014 DDD/1000 constituting 464.1 unites was with 36 unites less than mentioned medium, or in other words with 
30% (198.3 unites) less than consumption in 2009.
2. The rate of parenteral forms compared with entral forms of consumption was changed significantly from 86% and 14% 
in 2009 to 74.8% and 25.2% in 2014 respectively. For cephalosporin's this rate constituted only 9.3% in 2014.
3. Estimation of consumption of antimicrobial medical remedies for systemic use in DDD per day and 1000 occupied bed 
days has permitted an appreciation of therapeutical effect on 1000 patients (or occupied bed days) and the comparison 
with the consumption of antibacterial in hospitals worldwide.
4. Information of institution team doctors and other measures about optimization antibiotic usage changed significantly the 
attitude towards the treatment of all groups of the antimicrobial medical remedies.
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